REGENXBIO Inc.

NASDAQ:RGNX

Biotechnology

Healthcare
$7.26 +1.97%

+$0.16 today

Market cap
$480.05M
Beta
1.03
P/E (TTM)
-1.5
EPS (TTM)
-$5.53
52W Low $5.46High $16.19

Volume 0.70M

Average 1.24M

RGNX Tax Payables

Taxes owed to authorities that have not yet been paid.

REGENXBIO Inc.NASDAQ: RGNX

Tax Payables · Q1 FY2026 · quarter ended Mar 2026

Tax payables remains negative

Q1 FY2026 tax payables was $0, compared with $0 a year earlier.

Context

  • Tax payables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Tax payables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Tax Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Tax Payables history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Tax Payables vs competitors

How RGNX compares with its peers on the latest reported figures

  • RGNX's Mar 2026 tax payables of $0 is the highest of the 10 companies compared; the peer median is $0.
  • Tax payables amounts to 0.0% of total assets for RGNX, versus a peer median of 0.0%.
RGNX Competitors Peer median
Tax Payables for RGNX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RGNXREGENXBIO Inc.Mar 2026$0 ——0.0%
QUREuniQure N.V.Mar 2026$0 ——0.0%
PGENPrecigen, Inc.Jun 2026$0 ——0.0%
MGTXMeiraGTx Holdings plcMar 2026$0 ——0.0%
SLDBSolid Biosciences Inc.Mar 2026$0 ——0.0%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$0 ——0.0%
OCGNOcugen, Inc.Mar 2026$0 ——0.0%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
VYGRVoyager Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding RGNX) $0——0.0%

Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents345.21M96.95M34.52M57.53M34.47M
Short-term Investments112.23M267.69M240.74M177.16M195.6M
Net Receivables32.44M30.29M26.34M21.57M27.38M
Inventory00000
Other Current Assets10.2M7.14M18.85M12.68M11.9M
Total Current Assets518.83M415.98M334.97M278M281.28M
Property, Plant & Equipment (Net)192.45M206.8M192.59M171.31M152.01M
Goodwill00000
Intangible Assets00000
Long-term Investments391.91M200.56M38.87M10.18M15.13M
Tax Assets00000
Other Non-current Assets10.72M9.93M7.54M6.5M4.61M
Total Non-current Assets595.08M417.29M239M187.99M171.75M
Total Assets1.11B833.27M573.97M465.99M453.03M
Account Payables11.39M27.21M22.79M22.8M21.36M
Short-term Debt000047.9M
Tax Payables11.33M0000
Deferred Revenue3.33M1.83M148K115K10.45M
Other Current Liabilities57.74M66.67M86.04M51.92M20.97M
Total Current Liabilities130.47M130.43M130.27M103.19M118.1M
Long-term Debt0000147.41M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000018.94M
Other Non-current Liabilities134.21M97.84M49.73M29.01M638K
Total Non-current Liabilities219.13M186.64M131.96M103.14M232.2M
Total Liabilities349.61M317.07M262.23M206.34M350.3M
Common Stock4K4K4K5K5K
Retained Earnings(161.23M)(441.55M)(705.05M)(932.15M)(1.13B)
Accumulated OCI(2.57M)(15.4M)(4.43M)(741K)(687K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity764.3M516.2M311.74M259.65M102.73M
Total Debt86.68M94.8M89.29M82.03M260.52M
Net Debt(258.53M)(2.15M)54.77M24.51M226.05M

REGENXBIO Inc.

NASDAQ:RGNX

Intrinsic Alpha fair value

Locked

Current Price

$7.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.